San Francisco might have reached herd immunity
San Francisco's average of 13.7 new COVID-19 infections per day "is what herd immunity looks like," Dr. George Rutherford, a professor of epidemiology at the University of California, San Francisco, told The Guardian.
Rutherford is one of several experts who believe San Francisco is the first major U.S. city to achieve the long sought-after goal. "You're going to have single cases, but they're not going to propagate out," he said.
It's not entirely clear what the actual threshold is for herd immunity, but 68 percent of the northern California city's eligible residents are fully vaccinated against COVID-19, and 80 percent have received at least one shot, The Guardian reports. Those numbers are certainly in the neighborhood of scientists' herd immunity estimates, some of which are as high as 90 percent, and when adding the amount of people who have recovered from natural infections, it appears the coronavirus may have a hit a wall in San Francisco.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The city has some natural advantages, The Guardian notes, including the fact that it has a relatively small population of children (no vaccines have been approved for anyone younger than 12), and it's a compact place, geographically speaking, which "has allowed teams of health workers to go door-to-door to reach" people who may not otherwise have been willing or able to get their shots. Read more at The Guardian.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The best new music of 2024 by genre
The Week Recommends Outstanding albums, from pop to electro and classical
By The Week UK Published
-
Nine best TV shows of 2024 to binge this Christmas
The Week Recommends From Baby Reindeer and Slow Horses to Rivals and Shogun, here are the critics' favourites
By The Week UK Published
-
Crossword: December 28, 2024
The Week's daily crossword puzzle
By The Week Staff Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published